SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Andrew H who wrote (445)8/18/1997 8:51:00 AM
From: Henry Niman   of 2173
 
Andy, The fact that 25% of type I participants elected not to continue taking the drug may just be a natural outcome of the effectiveness of the drug. About 50% of the paticipants received Pramlintide, while 50% received the placebo. I don't know exactly who decide to use the drug after completion of the study, but the 25% who elected not to continue could have come almost exclusively from the 50% of the intent-to-treat group who saw no benefit. In other words, about 25% of the total group took the drug and didn't see a 0.5% reduction. About 25% of the group did see such a reduction. About 50% of the group received the placebo. Thus the 75% could be all of the patients on the placebo, and all of the patients who saw the benefit. Of course if the placebo group responds as the treated group did, then the % who elect to continue on the drug could easily drop to 50% (100% of those who see a benefit).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News